Pasireotide and Octreotide Stimulate Distinct Patterns of sst(2A) Somatostatin Receptor Phosphorylation

Pasireotide (SOM230) is currently under clinical evaluation as a successor compound to octreotide for the treatment of acromegaly, Cushing’s disease, and carcinoid tumors. Whereas octreotide acts primarily via the sst(2A) somatostatin receptor, pasireotide was designed to exhibit octreotide-like sst...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Mol Endocrinol
Main Authors: Pöll, Florian, Lehmann, Diana, Illing, Susann, Ginj, Mihaela, Jacobs, Stefan, Lupp, Amelie, Stumm, Ralf, Schulz, Stefan
Format: Artigo
Sprog:Inglês
Udgivet: Endocrine Society 2010
Fag:
Original Research
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC5428126/
https://ncbi.nlm.nih.gov/pubmed/20051480
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/me.2009-0315
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker